In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (NASDAQ: DNDN), a company that has underperformed recently, to shareholders' chagrin. Brenton looked at the company's recent SEC filings and gives us a few interesting pieces of information about the company he gleaned from them. For one thing, the company had been sitting on some zero-cost antigen inventory, and benefiting from that wasn't being recognized as an expense. Second, the company made a sharp move by selling its royalty rights to Merck's (NYSE: MRK) hepatitis C drug Victrelis last year for $125 million.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What's Changed With Dendreon?
A close look at the books at Dendreon.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.